For people with relapsing-remitting multiple sclerosis (MS), a new study has found that the drug ofatumumab is more effective than teriflunomide at helping people across racial and ethnic groups reach a period of no disease activity. The study is published in the July 17, 2024, online issue of Neurology(r), the medical journal of the American Academy of Neurology.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.